Formulation and Characterization of Nanoparticles Loaded with Cefadroxil
Hemalatha.C. N*, Yeswanth
Prasanna Kumar. B, Vijey Anandhi. M
School of Pharmaceutical Sciences,
Vels University, Chennai, Tamilnadu, India
*Corresponding Author E-mail: hodpchemistry@velsuniv.ac.in
ABSTRACT:
Nanotechnology encompass a
range of techniques rather than a single discipline and stretches across the
whole spectrum of science, touching medicines, physics, engineering and
chemistry. Targeted delivery of ingredients to a particular cell type or
receptor. Capable of heat triggered local release. Nanoparticles
are made up of non-biodegradable polymers such as methylmethacrylate
or it can also be made from biodegradable polymers such as alkylcyano
acrylate and albumin. Numerous methods exist for the manufacture of
preparation of nanoparticles, allowing extensive
modulation of their structure, composition and physiochemical properties. Formulation
of nanoparticles of Cefadroxil
using Albumin and Eudragit RL 100 in the ratios 1:1 and
1:2. Characterization of nanoparticles and invitro release of drugs has been carried out. In vitro release studies of each polymer
was evaluated the synthetic polymer was exhibiting more extended release than
natural polymer and the proportion have its influence in extending the release
rate of the drug. The half-life of drug using Albumin loaded is 4hr and using Eudragit RL 100 is 4-5hr. Anti-bacterial studies has
been done to confirm the anti-bacterial activity.
KEYWORDS: Nanoparticles, Albumin, Eudragit RL 100, antibacterial.
INTRODUCTION:
Nanotechnology is the science
of the extremely tiny. It involves the study and use of materials on an
unimaginably small scale. Nano refers to a nanometre
(nm). (1)One nanometre millionth of a millimetre or about one eighty
thousandth the width of a human hair. Nanotechnology encompass a range of
techniques rather than a single discipline and stretches across the whole spectrum
of science, touching medicines, physics, engineering and chemistry.
Nanotechnology
in Medicines:
Nanotechnology involve the
identification of precise targets (cells and receptors) related to specific
clinical conditions and choice of the appropriate Nano
carriers to achieve the required responses while minimizing the side effects.(2)
Nanoparticles:
Nanoparticles consists of
macromolecular materials and can be used therapeutically for e.g. as adjuvant
in vaccines or drug carriers in which the active principle (drug or
bioavailability active material) is dissolved, entrapped or encapsulated and
which the active principle is absorbed or attached.
Carriers
Used in The Preparation of Nanoparticles:
The polymers used for the
preparation of nanoparticles are either Amphiphilic macromolecules, obtained from natural sources,
hydrophilic polymers or synthesized chemically.(3)
Characterization:
Physiological methods for the
characterization of nanoparticles are listed. Size is
their most prominent feature, although other parameters, such as density,
molecular weight, and crystallinity, influence nanoparticles release and degeneration properties, whereas
surface charge, hydrophilicity and hydrophobicity significantly influence the interaction with
the biological environment after administration to humans and animals and the
resulting body distribution.(4,5,6)
INTRODUCTION
ABOUT THE DRUG
These are a group of
semi-synthetic antibiotic derived from “Cephalosporin –C” obtained from fingers
“Cephalosporin”. They are chemically related to penicillin. Cefadroxil is a broad-spectrum antibiotic of the cephalosporin type, effective in Gram-positiveand Gram-negative bacterial infections. It is a bactericidal antibiotic.
HALF
LIFE: About 1-4 hour to 2-6 hour.
POLYMER
PROFILE EUDRAGIT RL 100:
EUDRAGIT RL
100 is a copolymer of ethyl acrylate, methyl methacrylate and a low content of methacrylic
acid ester with quaternary ammonium groups. The ammonium groups are present as
salts and make the polymers permeable. Physical properties: It is a solid substance in
form of colourless, clear to cloudy granules with a
faint amine-like odour.
SOLUBILITY:
Table - 1
Type |
AA |
DCM |
SEA |
1N HCl |
1N NaOH |
PE |
W |
Eudragit RL 100 |
S |
S |
S |
- |
- |
I |
I |
Where, AA= Acetone and Alcohols
; DCM= Di-chloromethane; SEA=Solvent Ethyl acetate; PE= Petroleum ether; W= Water;
S= soluble; I= Insoluble or immiscible ; Alcohols including ethanol, methanol
and propane 2 – ol.
MATERIALS AND METHODS:
Preparation
of Cefadroxil Loaded Egg Albumin and Eudragit Nanoparticles:
Drug polymer ratio
Drug : polymer
1 : 1
1 : 2
Table - 2
S.No |
Egg albumin nanoparticles |
Eudragitnano particles |
1 |
Cefadroxil |
Cefadroxil |
2 |
Albumin
|
Eudragit RL-100 |
3 |
10%
HCl |
Chloroform
|
4 |
5%
NaOH |
Gelatin
|
5 |
Acetone |
Cooling
centrifuge |
6 |
4%
Gluteraldehyde |
Ultra
Sonicator |
7 |
Electronic
single pan balance |
Electronic
single pan balance |
8 |
pH
meter |
Vacuum
drier |
9 |
U.V.
Visible Spectrophotometer |
|
10 |
Centrifuge |
|
11 |
Vacuum
Drier |
|
12 |
Ultra
Sonicator |
|
Procedure of egg albumin nanoparticles:
Nanoparticles were
prepared by pH – coaservation method. 100mg of egg
albumin was taken in 50ml beaker and mixed with 100mg of the drug solution in
10% HCl then adjusted the pH to 8. The solution was sonicated by Ultra Sonicator with
5% NaOH solution and acetone was added drop wise from
a syringe until the solution become turbid. The formed particles are cross
linked by adding 100ml of 4% gluteraldehyde solution
was sonicated continuously for 3 hours at room
temperature.(7,8) After the cross linking stage, the egg albumin nanoparticles were centrifuged at 5000rpm for 30 minutes.
After centrifuging the supernatant liquid was removed and the suspension was
washed till it is free from acetone and then finally dried in a vacuum drier.(9)
Procedure of eudragit nanoparticles:
The drug Cefadroxil polymer Eudragit are
accurately weighed and Cefadroxil was dissolved in
water and Eudragit in chloroform. The two solutions
are mixed and were emulsified by ultrasonification
for 45 minutes at 15°C in an aqueous 0.5% W/W Gelatin
solution.(9) The solvent evaporate during 45 minutes at 40°C under
continuous sonification. The nanoparticles
formed is separated by Fractional centrifugation using a cooling centrifuge. The
solution was centrifuged for about 15,000 rpm at 20°C for 15 minute. The
supernatant fluid was discarded. The product was dried in vacuum drier.
Standard curve of Cefadroxil has been
estimated. Dissolution study has been carried out.
Fig. 2: Standard curve for pure drug (CEFADROXIL)
Characterization
Drug Content Analysis:
The drug content
for Albumin loaded nanoparticles was analysed by
adding 100ml of 1% hydrochloric acid solution with 0.1 ml of formulated
nanoparticle and kept at room temperature for 24 hrs. (10, 11,12, 13)
Drug loaded
capacity =
mg of drug bound
by total amount of nanoparticles
Total amount of applied drug (mg)
The method adopted
to carry out the invitro antibacterial activity was
filter paper disc and media used was Muehler Hinton
Agar.
RESULTS AND DISCUSSIONS:
Shorter biological
half-life may necessities. Repeated administration of drug, which may reduce
patient convenience and compliance Cephalosporin group of antibiotics, cefadroxil exhibits a shorter biological half-life, with
wide anti-bacterial activity which required frequent doses, in order to reduce
the toxicity and frequency Cefadroxil nanoparticle
was formulated. Nanoparticle carrier of Cefadroxil
was formulated using a natural polymer Albumin and a synthetic polymer Eudragit in the ratio 1:1 and 1:2. Two methods were adopted
for the formulation one method adopted was the cross-linking method by using Eudragit polymer and the other being the pH-coacervation method using albumin as carrier drug polymer
ratio and the cross link was presented.
Table – 3 Synthetic and Drug Polymer Ratio
S.NO |
Batch Code |
Amount of drug |
Amount of polymer |
Conc of cross-links agent |
Drug-polymer ratio |
1 |
A1 |
100mg |
100mg |
4% Gluteraldehyde |
1:1 |
2 |
A2 |
200mg |
200mg |
4% Gluteraldehyde |
1:2 |
3 |
E1 |
100mg |
100mg |
0.5% w/w Gelatin |
1:1 |
4 |
E2 |
200mg |
200mg |
0.5% w/w Gelatin |
1:2 |
A1 = 1:1; E1 = 1:1; A2 = 1:2; E2
= 1:2
Table – 4 Absorbance and Concentration
S.No |
Formulations |
Absorbance |
Concentration % |
1 |
A1 |
0.96 |
50.52% |
2 |
A2 |
0.89 |
46.84% |
3 |
E1 |
0.90 |
47.37% |
4 |
E2 |
0.93 |
48.94% |
A1 = 1:1 ; E1 = 1:1; A2 = 1:2; E2
= 1:2
Table – 5 Drug
release rate of pure drug (CEFADROXIL)
Time in hrs |
Absorbance |
Conc
mg/ml |
Conc
mg/900ml |
% Release |
30 min |
0.5428 |
28.57 |
25.72 |
25.72 |
1hr |
0.7486 |
39.4 |
35.46 |
35.46 |
2hr |
1.1315 |
59.55 |
53.6 |
53.6 |
3hr |
1.5276 |
80.4 |
72.36 |
72.36 |
4hr |
1.9025 |
100.13 |
90.12 |
90.12 |
Table
– 6 Drug release rate of ALBUMIN loaded Nano
particles (Ratio 1:1)
Time in hrs |
Absorbance |
Conc
mg/ml |
Conc
mg/900 ml |
% Release |
1hr |
0.6126 |
32.24 |
29.02 |
29.02 |
2hr |
0.788 |
41.47 |
37.33 |
37.33 |
3hr |
0.9611 |
50.59 |
45.53 |
45.53 |
4hr |
1.1136 |
58.61 |
52.75 |
52.75 |
5hr |
1.3874 |
73.02 |
65.72 |
65.72 |
6hr |
1.5436 |
81.24 |
73.12 |
73.12 |
7hr |
1.7955 |
94.5 |
85.05 |
85.05 |
Table – 7 Drug release rate of
ALBUMIN loaded Nano particles (Ratio 1:2)
Time in hrs |
Absorbance |
Conc
mg/ml |
Conc
mg/900 ml |
% Release |
1hr |
0.488 |
25.69 |
23.12 |
23.12 |
2hr |
0.6232 |
33.06 |
29.76 |
29.76 |
3hr |
0.8148 |
42.88 |
38.6 |
38.6 |
4hr |
1.001 |
52.68 |
47.42 |
47.42 |
5hr |
1.273 |
67 |
60.3 |
60.3 |
6hr |
1.4197 |
74.72 |
67.25 |
67.25 |
7hr |
1.6747 |
88.14 |
79.33 |
79.33 |
8hr |
1.8698 |
98.41 |
88.57 |
88.57 |
Table – 8 Drug release rate of
EUDRAGIT loaded Nano particles (Ratio 1:1)
Time in hrs |
Absorbance |
Conc
mg/ml |
Conc
mg/900 ml |
% Release |
1hr |
0.3614 |
19.02 |
17.12 |
17.12 |
2hr |
0.4678 |
24.62 |
22.16 |
22.16 |
3hr |
0.5979 |
31.46 |
28.32 |
28.32 |
4hr |
0.7653 |
40.28 |
36.25 |
36.25 |
5hr |
0.9204 |
48.44 |
43.6 |
43.6 |
6hr |
1.1214 |
59.02 |
53.12 |
53.12 |
7hr |
1.2947 |
68.14 |
61.33 |
61.33 |
8hr |
1.4682 |
77.28 |
69.55 |
69.55 |
9hr |
1.6331 |
85.96 |
77.36 |
77.36 |
Table – 9 Drug release rate of
EUDRAGIT loaded Nano particles (Ratio 1:2)
Time in hrs |
Absorbance |
Conc
mg/ml |
Conc
mg/900 ml |
% Release |
1hr |
0.2603 |
13.7 |
12.33 |
12.33 |
2hr |
0.3884 |
20.44 |
18.4 |
18.4 |
3hr |
0.487 |
25.63 |
23.07 |
23.07 |
4hr |
0.6365 |
33.5 |
30.15 |
30.15 |
5hr |
0.7963 |
41.91 |
37.72 |
37.72 |
6hr |
0.9578 |
50.41 |
45.37 |
45.37 |
7hr |
1.1159 |
58.73 |
52.86 |
52.86 |
8hr |
1.278 |
67.27 |
60.54 |
60.54 |
9hr |
1.4836 |
78.07 |
70.26 |
70.26 |
Fig.
3 Comparison and release rate of pure drug and formulated nanoparticles
Comparison and release rate
of pure drug and formulated nanoparticles
Table
– 10
Name of strain |
Zone of inhibition in nm |
||||
Bacterial strain |
Standard |
A1 |
A2 |
E1 |
E2 |
Klebsiella |
19 |
16 |
14 |
11 |
10 |
Streptococcus |
20 |
11 |
15 |
12 |
13 |
Staphylococcus |
22 |
17 |
12 |
18 |
11 |
In vitro antibacterial studies was done to confirm the
efficacy of the formulation by measuring the zone of inhibition and the result
were presented in table X.
Anti bacterial activity of
formulated nono particles
SUMMARY
AND CONCLUSION:
Cefadroxil an antibacterial drug was loaded in Nano particulate carrier using albumin and polymethacrylate polymers in different ratios by cross
linking method and pH-coacervation method. Time,
speed of sonication and temperature were standardized to yield good
formulation. Drug content and loading
analysis confirms the entrapment of drug in the carrier. In vitro release
studies of each polymer was evaluated the synthetic polymer was exhibiting more
extended release than natural polymer and the proportion have its influence in
extending the release rate of the drug. Invitro
anti-bacterial studies confirms the efficacy of the antibacterial agent in the
formulations, which was done by measuring zone of inhibition. Above studies
reveals that the antibacterial activity of cefadroxil
can be maintained and extended over a period of time, reducing the frequency of
doses.
REFERENCE:
1.
Aliautdin,
R. N., V. E. Petrov, et al. (1998). "[The
delivery of loperamide to the brain by using polybutyl cyanoacrylate nanoparticles]." Eksp Klin Farmakol 61(1): 17-20.
2.
Allemann,
E., J. C. Leroux, et al. (1993). "In vitro
extended-release properties of drug-loaded poly(DL-lactic acid) nanoparticles produced by a salting-out procedure." Pharmacetical Research 10(12): 1732-7.
3.
Coester,
C. J., K. Langer, et al. (2000). "Gelatin nanoparticles by two step desolvation--a
new preparation method, surface modifications and cell uptake." Journal of
Microencapsulation 17(2): 187-93.
4.
Couvreur,
P., E. Fattal, et al. (1991). "Liposomes and nanoparticles in
the treatment of intracellular bacterial infections."Pharm
Res 8(9): 1079-86.
5.
Fontana,
G., G. Pitarresi, et al. (1998). "Preparation,
characterization and in vitro antimicrobial activity of ampicillin-loaded
polyethylcyanoacrylate nanoparticles."
Biomaterials 19(11-12): 1009-17.
6.
Fresta, M., G. Cavallaro, et al. (1996).
"Preparation and characterization of polyethyl-2-cyanoacrylate nanocapsules containing antiepileptic drugs."
Biomaterials 17(8): 751-8.
7.
Guise,
V., J. Y. Drouin, et al. (1990). "Vidarabine-loaded nanoparticles:aphysicochemical
study." Pharm Res 7(7): 736- 41.
8.
Gulyaev,
A. E., S. E. Gelperina, et al. (1999). "Significant
transport of doxorubicin into the brain with polysorbate
80- coated nanoparticles." Pharm
Res 16(10): 1564-9.
9.
Guzman,
M., J. Molpeceres, et al. (1993). "Formation
and characterization of cyclosporine-loaded nanoparticles."
Journal of Pharmaceutical Sciences 82(5): 498-502.
10.
Kreuter, J. (1991). "Liposomes and nanoparticles as vehicles for antibiotics." Infection
19(Suppl 4(1)): S224-8.
11.
Kreuter, J. (1994). "Drug targeting with nanoparticles."
European Journal of Drug Metabolism and Pharmacokinetics 19(3): 253-6.
12.
Kreuter,
J., R. N. Alyautdin, et al. (1995). "Passage of
peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles)." Brain Research 674(1): 171-4.
13.
Lin,
W., M. C. Garnett, et al. (2001). "Preparation
and characterisation of rose Bengal-loaded
surface-modified albuminnanoparticles." Journal
of Control Release 71(1): 117-26.
Received on 29.08.2016
Modified on 30.09.2016
Accepted on 01.11.2016 ©
RJPT All right reserved
Research J. Pharm. and Tech. 2017; 10(1): 183-187.
DOI: 10.5958/0974-360X.2017.00040.3